High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade

Michael K. Kießling(German Cancer Research Center), Reinhard Dummer(University Hospital of Zurich)

Blood

January 6, 2011

10.1182/blood-2010-09-305128

Cited by 77

Related Papers

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

|New England Journal of Medicine|2011|7.7k

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

|Science|2015|3k

Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma

|New England Journal of Medicine|2017|1.5k

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

|Nature|2010|1.4k

Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)

|Blood|2007|1.4k